254 related articles for article (PubMed ID: 30854783)
21. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
Iino M; Sakamoto Y; Sato T
Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
[TBL] [Abstract][Full Text] [Related]
22. Use of thrombopoietin receptor agonists for immune thrombocytopenia in pregnancy: results from a multicenter study.
Michel M; Ruggeri M; Gonzalez-Lopez TJ; Alkindi S; Cheze S; Ghanima W; Tvedt THA; Ebbo M; Terriou L; Bussel JB; Godeau B
Blood; 2020 Dec; 136(26):3056-3061. PubMed ID: 32814348
[TBL] [Abstract][Full Text] [Related]
23. Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
Neunert CE
Hamostaseologie; 2019 Aug; 39(3):272-278. PubMed ID: 30646404
[TBL] [Abstract][Full Text] [Related]
24. The use of thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): a "real life" retrospective multicenter experience of the Rete Ematologica Pugliese (REP).
Mazza P; Minoia C; Melpignano A; Polimeno G; Cascavilla N; Di Renzo N; Specchia G
Ann Hematol; 2016 Jan; 95(2):239-44. PubMed ID: 26596973
[TBL] [Abstract][Full Text] [Related]
25. Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison.
Cooper KL; Fitzgerald P; Dillingham K; Helme K; Akehurst R
Int J Technol Assess Health Care; 2012 Jul; 28(3):249-58. PubMed ID: 22980701
[TBL] [Abstract][Full Text] [Related]
26. Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
Zhang X; Chuai Y; Nie W; Wang A; Dai G
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD012035. PubMed ID: 29178132
[TBL] [Abstract][Full Text] [Related]
27. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: A multicentre US study.
Al-Samkari H; Jiang D; Gernsheimer T; Liebman H; Lee S; Wojdyla M; Vredenburg M; Cuker A
Br J Haematol; 2022 May; 197(3):359-366. PubMed ID: 35179784
[TBL] [Abstract][Full Text] [Related]
28. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogs.
Fattizzo B; Pasquale R; Carpenedo M; Cantoni S; Auteri G; Gramegna D; D'Adda M; Napolitano M; Consonni D; Ruggeri M; Siragusa S; Rossi G; Vianelli N; Barcellini W
Haematologica; 2019 Oct; 104(10):e470-e473. PubMed ID: 30846501
[No Abstract] [Full Text] [Related]
29. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
30. Romiplostim is effective for eltrombopag-refractory aplastic anemia: results of a retrospective study.
Ise M; Iizuka H; Kamoda Y; Hirao M; Kida M; Usuki K
Int J Hematol; 2020 Dec; 112(6):787-794. PubMed ID: 32876852
[TBL] [Abstract][Full Text] [Related]
31. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
Al-Samkari H; Kuter DJ
Am J Hematol; 2018 Dec; 93(12):1501-1508. PubMed ID: 30187942
[TBL] [Abstract][Full Text] [Related]
32. Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports.
Gilreath JA; Wei M; Paul S; Parker CJ; Stenehjem DD; Rodgers GM
J Oncol Pharm Pract; 2019 Apr; 25(3):719-723. PubMed ID: 29357781
[TBL] [Abstract][Full Text] [Related]
33. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
34. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
35. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
Palandri F; Rossi E; Bartoletti D; Ferretti A; Ruggeri M; Lucchini E; Carrai V; Barcellini W; Patriarca A; Rivolti E; Consoli U; Cantoni S; Oliva EN; Chiurazzi F; Caocci G; Giuffrida G; Borchiellini A; Auteri G; Baldacci E; Carli G; Nicolosi D; Sutto E; Carpenedo M; Cavo M; Mazzucconi MG; Zaja F; De Stefano V; Rodeghiero F; Vianelli N
Blood; 2021 Aug; 138(7):571-583. PubMed ID: 33889952
[TBL] [Abstract][Full Text] [Related]
36. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists.
Ghadaki B; Nazi I; Kelton JG; Arnold DM
Transfusion; 2013 Nov; 53(11):2807-12. PubMed ID: 23451917
[TBL] [Abstract][Full Text] [Related]
37. Eltrombopag for Delayed Platelet Recovery and Secondary Thrombocytopenia Following Allogeneic Stem Cell Transplantation in Children.
Li S; Wu R; Wang B; Fu L; Zhu G; Zhou X; Ma J; Zhang L; Qin M
J Pediatr Hematol Oncol; 2019 Jan; 41(1):38-41. PubMed ID: 30080752
[TBL] [Abstract][Full Text] [Related]
38. Highly fluctuating thrombocytopenia developing in a patient with immune thrombocytopenia (ITP) while administering romiplostim.
Shinohara K; Kambara N
Intern Med; 2012; 51(11):1399-401. PubMed ID: 22687850
[TBL] [Abstract][Full Text] [Related]
39. Real-world evidence on clinical outcomes in immune thrombocytopenia treated with thrombopoietin receptor agonists.
Forsythe A; Schneider J; Pham T; Bhor M; Said Q; Allepuz A; Socorro O Portella MD; Kwon CS; Roy AN
J Comp Eff Res; 2020 May; 9(7):447-457. PubMed ID: 32175766
[No Abstract] [Full Text] [Related]
40. The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim.
Al-Samkari H; Schifferli A; Gonzalez-Lopez TJ
Br J Haematol; 2024 Apr; 204(4):1143-1145. PubMed ID: 38319005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]